SE PUEDE YA AFIRMAR QUE TARLATAMAB ( IMDELLTRA BY AMGEN ) SUPERA AMPLIAMENTE AL LURBINECTEDIN ( ZEPZELCA BY PHARMAMAR ) TANTO EN PRIMERA LÍNEA DE MANTENIMIENTO ... COMO EN SEGUNDA LINEA PARA EL TRATAMIENTO ESTÁNDAR DE SMALL CELL LUNG CANCER EXTENSIVE-STAGE .
And The Ride Hasn't Got Any Smoother In Recent Times Over The Last Year, With The Price 25% Lower In That Time . Furthermore, It's Down 11% in About a Quarter. That's Not Much Fun For Holders . ...